Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial-Reference-Cited by-同舟云学术

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial

Published:2020-10 Issue:10 Volume:21 Page:1317-1330
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Kumar Shaji K,Jacobus Susanna J,Cohen Adam D,Weiss Matthias,Callander Natalie,Singh Avina K,Parker Terri L,Menter Alexander,Yang Xuezhong,Parsons Benjamin,Kumar Pankaj,Kapoor Prashant,Rosenberg Aaron,Zonder Jeffrey A,Faber Edward,Lonial Sagar,Anderson Kenneth C,Richardson Paul G,Orlowski Robert Z,Wagner Lynne I,Rajkumar S Vincent

Funder

NCI

Publisher

Elsevier BV

Subject

Oncology

Reference35 articles.

1. The multiple myelomas—current concepts in cytogenetic classification and therapy;Kumar;Nat Rev Clin Oncol,2018

2. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma;Dimopoulos;Blood Cancer J,2020

3. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States;Costa;Blood Adv,2017

4. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients;Kumar;Leukemia,2014

5. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis;Munshi;JAMA Oncol,2017

Cited by 186 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum Free Light Chain Kinetics Is Predictive of Renal Response in Myeloma Patients With Renal Impairment—An ALLG Trial of Carfilzomib-Dexamethasone Therapy in Frontline and Relapse;Clinical Lymphoma Myeloma and Leukemia;2024-08

2. The ubiquitin-proteasome system in the regulation of tumor dormancy and recurrence;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-07

3. Multiple myeloma: 2024 update on diagnosis, risk‐stratification, and management;American Journal of Hematology;2024-06-28

4. Patient-Reported Outcomes in Phase 3 Clinical Trials for Blood Cancers: A Systematic Review;JAMA Network Open;2024-06-03

5. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma;New England Journal of Medicine;2024-06-03